These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9836498)

  • 1. Levels of soluble Fas/APO-1 in patients with Behçet's disease.
    Hamzaoui K; Hamzaoui A; Zakraoui L; Chabbou A
    Mediators Inflamm; 1998; 7(2):111-4. PubMed ID: 9836498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elevated levels of serum soluble Fas are associated with organ and tissue damage in systemic lupus erythematosus among Chinese.
    Hao JH; Ye DQ; Zhang GQ; Liu HH; Dai H; Huang F; Pan FM; Su H; Dong MX; Chen H; Wang Q; Zhang XJ
    Arch Dermatol Res; 2006 Jan; 297(7):329-32. PubMed ID: 16328345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do elevated levels of serum-soluble fas contribute to the persistence of activated lymphocytes in systemic lupus erythematosus?
    Bijl M; van Lopik T; Limburg PC; Spronk PE; Jaegers SM; Aarden LA; Smeenk RJ; Kallenberg GG
    J Autoimmun; 1998 Oct; 11(5):457-63. PubMed ID: 9802929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus.
    Miret C; Font J; Molina R; Garcia-Carrasco M; Filella X; Ramos M; Cervera R; Ballesta A; Ingelmo M
    Anticancer Res; 2001; 21(4B):3053-9. PubMed ID: 11712810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum soluble Fas levels in patients with autoimmune rheumatic diseases.
    Sahin M; Aydintug O; Tunc SE; Tutkak H; Naziroğlu M
    Clin Biochem; 2007 Jan; 40(1-2):6-10. PubMed ID: 17056024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between serum levels of soluble Fas (CD95/Apo-1) with disease activity in systemic lupus erythematosus patients in Khorasan, Iran.
    Sahebari M; Hatef MR; Rezaieyazdi Z; Abbasi M; Abbasi B; Mahmoudi M
    Arch Iran Med; 2010 Mar; 13(2):135-42. PubMed ID: 20187668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
    Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
    Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levels of soluble E-selectin in patients with active Behcet's disease.
    Sari RA; Kiziltunç A; Taysi S; Akdemir S; Gündoğdu M
    Clin Rheumatol; 2005 Feb; 24(1):55-9. PubMed ID: 15338451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levels of soluble Fas/APO-1/CD95 in systemic lupus erythematosus and juvenile rheumatoid arthritis.
    Knipping E; Krammer PH; Onel KB; Lehman TJ; Mysler E; Elkon KB
    Arthritis Rheum; 1995 Dec; 38(12):1735-7. PubMed ID: 8849344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus.
    Lub-de Hooge MN; de Vries EG; de Jong S; Bijl M
    Ann Rheum Dis; 2005 Jun; 64(6):854-8. PubMed ID: 15564310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with systemic lupus erythematosus with high plasma levels of sFas risk relapse.
    van Lopik T; Bijl M; Hart M; Boeije L; Gesner T; Creasy AA; Kallenberg CG; Aarden LA; Smeenk RJ
    J Rheumatol; 1999 Jan; 26(1):60-7. PubMed ID: 9918241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
    Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
    J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity.
    Lee YJ; Kang SW; Song JK; Park JJ; Bae YD; Lee EY; Lee EB; Song YW
    Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S41-5. PubMed ID: 17949550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A possible role of Fas-ligand-mediated "reverse signaling" in pathogenesis of rheumatoid arthritis and systemic lupus erythematosus.
    Telegina E; Reshetnyak T; Moshnikova A; Proussakova O; Zhukova A; Kuznetsova A; Ivanov A; Paltsev M; Beletsky I
    Immunol Lett; 2009 Jan; 122(1):12-7. PubMed ID: 19010354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum sFas/sFasL ratio in systemic lupus erythematosus (SLE) is a function of age.
    Turi MC; D'Urbano M; Celletti E; Alessandri C; Valesini G; Paganelli R
    Arch Gerontol Geriatr; 2009; 49 Suppl 1():221-6. PubMed ID: 19836636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nitric oxide, lipid peroxidation and antioxidant defence system in patients with active or inactive Behçet's disease.
    Buldanlioglu S; Turkmen S; Ayabakan HB; Yenice N; Vardar M; Dogan S; Mercan E
    Br J Dermatol; 2005 Sep; 153(3):526-30. PubMed ID: 16120137
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological levels of apoptotic bodies, sFAS and TNF in lupus erythematosus.
    Alecu M; Coman G; Alecu S
    Rom J Intern Med; 2000-2001; 38-39():83-8. PubMed ID: 15529575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The levels of serum-soluble Fas in patients with rheumatoid arthritis and systemic sclerosis.
    Ateş A; Kinikli G; Turgay M; Duman M
    Clin Rheumatol; 2004 Oct; 23(5):421-5. PubMed ID: 15459814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MALDI-TOF/TOF-MS reveals elevated serum haptoglobin and amyloid A in Behcet's disease.
    Mao L; Dong H; Yang P; Zhou H; Huang X; Lin X; Kijlstra A
    J Proteome Res; 2008 Oct; 7(10):4500-7. PubMed ID: 18754684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated levels of soluble fractalkine in active systemic lupus erythematosus: potential involvement in neuropsychiatric manifestations.
    Yajima N; Kasama T; Isozaki T; Odai T; Matsunawa M; Negishi M; Ide H; Kameoka Y; Hirohata S; Adachi M
    Arthritis Rheum; 2005 Jun; 52(6):1670-5. PubMed ID: 15934075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.